文献速递神经肿瘤

RAGE基因敲除通过抑制半乳糖凝集素-3表达减弱胶质瘤进展并增强肿瘤免疫反应

RAGE ablation attenuates glioma progression and enhances tumor immune responses by suppressing galectin-3 expression.
PubMed 文献 · Neuro Oncol · 2023-01-01

研究在两种同基因小鼠胶质瘤模型(GL261和K-Luc)中,用shRNA和CRISPR/Cas9技术抑制RAGE表达后颅内植入,评估肿瘤生长、侵袭和炎症反应。结果显示细胞内RAGE敲除通过抑制AKT和ERK1/2活性及下调MMP9表达阻断胶质瘤生长和侵袭,并通过下调半乳糖凝集素-3增强肿瘤炎症反应及免疫检查点阻断疗效。

要点

  • 细胞内RAGE敲除可阻断胶质瘤生长和侵袭,抑制AKT和ERK1/2活性并下调MMP9表达。
  • RAGE抑制通过下调半乳糖凝集素-3增强肿瘤炎症反应。
  • RAGE抑制增强了免疫检查点阻断的免疫治疗反应。

核心结论

  • 细胞内RAGE敲除抑制胶质瘤进展、侵袭和免疫逃逸相关的多条细胞通路。
  • 这些发现强烈支持将RAGE敲除开发为恶性胶质瘤的治疗策略。

研究设计与样本

  • 在两种同基因小鼠胶质瘤模型(GL261和K-Luc)中,用shRNA和CRISPR/Cas9技术在颅内植入前抑制RAGE表达。
  • 通过组织学、生存分析、Nanostring和流式细胞术检查肿瘤生长、侵袭和炎症反应。

主要发现

  • 细胞内RAGE敲除通过抑制AKT和ERK1/2活性及下调MMP9表达,阻断胶质瘤生长和侵袭。
  • 在两种胶质瘤模型中,RAGE抑制通过下调半乳糖凝集素-3表达增强肿瘤炎症反应。
  • RAGE抑制增强了针对免疫检查点阻断的免疫治疗反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant gliomas consist of heterogeneous cellular components that have adopted multiple overlapping escape mechanisms that overcome both targeted and immune-based therapies. The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily that is activated by diverse proinflammatory ligands present in the tumor microenvironment. Activation of RAGE by its ligands stimulates multiple signaling pathways that are important in tumor growth and invasion. However, treatment strategies that only target the interaction of RAGE with its ligands are ineffective as cancer therapies due to the abundance and diversity of exogenous RAGE ligands in gliomas. METHODS: As an alternative approach to RAGE ligand inhibition, we evaluated the genetic ablation of RAGE on the tumorigenicity of 2 syngeneic murine glioma models. RAGE expression was inhibited in the GL261 and K-Luc gliomas by shRNA and CRSPR/Cas9 techniques prior to intracranial implantation. Tumor growth, invasion, and inflammatory responses were examined by histology, survival, Nanostring, and flow cytometry. RESULTS: Intracellular RAGE ablation abrogated glioma growth and invasion by suppressing AKT and ERK1/2 activities and by downregulating MMP9 expression. Interestingly, RAGE inhibition in both glioma models enhanced tumor inflammatory responses by downregulating the expression of galectin-3 and potentiated immunotherapy responses to immune checkpoint blockade. CONCLUSIONS: We demonstrated that intracellular RAGE ablation suppresses multiple cellular pathways that are important in glioma progression, invasion, and immune escape. These findings strongly support the development of RAGE ablation as a treatment strategy for malignant gliomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang IY, Liu S, Zhang L, et al. RAGE ablation attenuates glioma progression and enhances tumor immune responses by suppressing galectin-3 expression. Neuro Oncol. 2023. PMID: 36394567. doi:10.1093/neuonc/noac250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。